Fig. 6

Progression-free survival analysis for subset of 166 non-squamous carcinoma patients with available mutation status of KRAS and STK11 genes, using (a) clinical model (BMI, smoking status) (b) combination model (radiomic phenotypes, radiological variables (SUVmax, longest tumor diameter at baseline), pathological variables (PD-L1 expression, KRAS expression, STK11 expression) (c) combination clinical model (d) multiomic graph phenotypes and (e) multiomic graph clinical model.